- ►angrylapdog.com VV McLaughlin, SL Archer, DB Badesch, RJ … - Journal of the American College of Cardiology, 2009 - Elsevier This document has been developed by the American College of Cardiology
Foundation (ACCF) Task Force on Expert Consensus Documents (ECDs), and was
cosponsored by the American Heart Association (AHA). Expert Consensus ... Cited by 20 - Related articles - All 19 versions
C Vlachopoulos, D Terentes-Printzios, N … - Current Pharmaceutical Design, 2009 - ingentaconnect.com Abstract: Phosphodiesterase type-5 (PDE5) inhibitors are widely used as
first-line therapy for erectile dysfunction (ED). Their efficacy and safety
combined with an increasing understanding of cyclic guanosine monophosphate ... Cited by 2 - Related articles
- ►ersj.org.uk MM Hoeper, H Gall, HJ Seyfarth, M Halank, HA … - European Respiratory Journal, 2009 - Eur Respiratory Soc MM Hoeper, 1 H Gall, 2 HJ Seyfarth, 3 M Halank, 4 HA Ghofrani, 2 J Winkler, 3 H
Golpon, 1 KM ... Olsson, 1 N Nickel, 1 C Opitz, 5 R Ewert, 6 ... From the 1
Department of Respiratory Medicine, Hannover Medical School, Hannover, 2 ... Cited by 2 - Related articles - All 8 versions
E Gruenig, E Michelakis, JL Vachiery, CD … - The Journal of Clinical Pharmacology, 2009 - jcp.sagepub.com This study investigated the acute pharmacodynamic effects of sildenafil in
patients with pulmonary arterial hypertension (PAH) and concomitant bosentan
treatment, in view of a mutual pharmacokinetic interaction between the 2 ... Cited by 2 - Related articles - All 3 versions
R Souza, C Jardim - European Respiratory Review, 2009 - Eur Respiratory Soc Past decades have witnessed an increasing interest in the field of pulmonary
arterial hypertension (PAH). The large number of publications related to PAH
reflects this interest. As a result, in contrast to 15 yrs ago, there are ... Cited by 2 - Related articles - All 2 versions
K Boutet, D Montani, X Jais, A Yaici, O … - Therapeutic Advances in Respiratory Disease, 2008 - tar.sagepub.com Abstract: Pulmonary arterial hypertension (PAH) is characterized by
vasoconstriction, in situ thrombosis, and vascular remodeling of small pulmonary
arteries inducing increased pulmonary arterial resistance. Conventional ... Cited by 1 - Related articles - All 7 versions
JL Vachiery, G Coghlan - European Respiratory Review, 2009 - Eur Respiratory Soc The onset and progression of pulmonary arterial hypertension (PAH) in patients
with systemic sclerosis (SSc) can be particularly aggressive; however, effective
treatments are available. Therefore, early identification of patients with ... Cited by 1 - Related articles
N Galie, L Negro, G Simonneau - European Respiratory Review, 2009 - Eur Respiratory Soc There is a strong clinical rationale for combination therapy in pulmonary
arterial hypertension (PAH), as several pathological pathways have been
implicated in its pathogenesis and no single agent has yet been shown to ... Cited by 1 - Related articles
T Thenappan, HI Palevsky - International journal of clinical practice. Supplement, 2009 - ncbi.nlm.nih.gov 1: Int J Clin Pract Suppl. 2009 Sep;(162):42-4. Long-term outcomes in
pulmonary arterial hypertension. Thenappan T, Palevsky HI. ... Cited by 1 - Related articles - All 3 versions
KM Olsson, MM Hoeper - Drug discovery today, 2009 - Elsevier Pulmonary arterial hypertension (PAH) has evolved from an untreatable condition
to a disease for which several classes of drugs have now been approved,
including various prostanoids, endothelin receptor antagonists and ... Cited by 1 - Related articles - All 3 versions
